Cavitary_NP Pneumonia_NP in_IN an_DT AIDS_NP Patient_NP Caused_NP by_IN an_DT Unusual_NP Bordetella_NP bronchiseptica_NP Variant_NP Producing_NP Reduced_NP Amounts_NP of_IN Pertactin_NP and_CC Other_JJ Major_JJ Antigens_NNS Although_IN Bordetella_NP bronchiseptica_NP can_MD infect_VB and_CC colonize_VB immunocompromised_JJ humans_NNS ,_, its_PP$ role_NN as_IN a_DT primary_JJ pathogen_NN in_IN pneumonia_NN and_CC other_JJ respiratory_JJ processes_NNS affecting_VBG those_DT patients_NNS remains_VBZ controversial_JJ ._SENT A_DT case_NN of_IN cavitary_JJ pneumonia_NN caused_VBN by_IN B._NP bronchiseptica_NP in_IN an_DT AIDS_NP patient_NN is_VBZ presented_VBN ,_, and_CC the_DT basis_NN of_IN the_DT seemingly_RB enhanced_VBN pathogenic_JJ potential_NN of_IN this_DT isolate_NN (_( designated_VBN 814_CD )_) is_VBZ investigated_VBN ._SENT B._NP bronchiseptica_NP was_VBD the_DT only_JJ microorganism_NN recovered_VBN from_IN sputum_NN ,_, bronchoalveolar_JJ lavage_NN fluid_NN ,_, and_CC samples_NNS taken_VBN through_IN the_DT protected_JJ brush_NN catheter_NN ._SENT Unlike_IN previous_JJ work_NN reporting_VBG the_DT involvement_NN of_IN B._NP bronchiseptica_NN in_IN cases_NNS of_IN pneumonia_NN ,_, antibiotic_JJ treatment_NN selected_VBN on_IN the_DT basis_NN of_IN in_IN vitro_NN antibacterial_NN activity_NN resulted_VBN in_IN clearance_NN of_IN the_DT infection_NN and_CC resolution_NN of_IN the_DT pulmonary_JJ infiltrate_NN ._SENT Although_IN isolate_NN 814_CD produced_VBD reduced_VBN amounts_NNS of_IN several_JJ major_JJ antigens_NNS including_VBG at_IN least_JJS one_CD Bvg-activated_JJ factor_NN (_( pertactin_NN )_) ,_, the_DT molecular_JJ basis_NN of_IN this_DT deficiency_NN was_VBD found_VBN to_TO be_VB BvgAS_NP independent_JJ since_IN the_DT defect_NN persisted_VBD after_IN the_DT bvgAS_NNS locus_NN of_IN isolate_NN 814_CD was_VBD replaced_VBN with_IN a_DT wild-type_NN bvgAS_NN allele_NN ._SENT Despite_IN its_PP$ prominent_JJ phenotype_NN ,_, isolate_VBP 814_CD displayed_VBN only_RB a_DT modest_JJ yet_CC a_DT significant_JJ deficiency_NN in_IN its_PP$ ability_NN to_TO colonize_VB the_DT respiratory_JJ tracts_NNS of_IN immunocompetent_JJ rats_NNS at_IN an_DT early_JJ time_NN point_NN ._SENT Interestingly_RB ,_, the_DT antibody_NN response_NN elicited_VBN by_IN isolate_NN 814_CD in_IN these_DT animals_NNS was_VBD almost_RB undetectable_JJ ._SENT We_PP propose_VBP that_RB isolate_VB 814_CD may_MD be_VB more_RBR virulent_JJ in_IN immunocompromised_JJ patients_NNS due_JJ ,_, at_IN least_JJS in_IN part_NN ,_, to_TO its_PP$ innate_JJ ability_NN to_TO produce_VB low_JJ amounts_NNS of_IN immunogenic_JJ factors_NNS which_WDT may_MD be_VB required_VBN at_IN only_JJ normal_JJ levels_NNS for_IN the_DT interaction_NN of_IN this_DT pathogen_NN with_IN its_PP$ immunocompetent_JJ natural_JJ hosts_NNS ._SENT Bordetella_NP bronchiseptica_NP ,_, a_DT small_JJ pleomorphic_JJ gram-negative_JJ coccobacillus_NN ,_, is_VBZ a_DT common_JJ upper_JJ respiratory_JJ tract_NN pathogen_NN in_IN many_JJ domestic_JJ and_CC wild_JJ animals_NNS and_CC causes_VBZ respiratory_JJ diseases_NNS in_IN a_DT broad_JJ variety_NN of_IN mammal_NN species_NNS such_JJ as_IN cats_NNS ,_, dogs_NNS ,_, horses_NNS ,_, rabbits_NNS ,_, and_CC swine_NN ,_, among_IN others_NNS ._SENT B._NP bronchiseptica_NP synthesizes_VBZ a_DT wide_JJ array_NN of_IN virulence_NN factors_NNS including_VBG adhesins_NNS like_IN filamentous_JJ hemagglutinin_NN (_( FHA_NP )_) ,_, fimbriae_NNS ,_, and_CC pertactin_NN and_CC toxins_NNS like_IN the_DT bifunctional_JJ adenylate_JJ cyclase_NN toxin/hemolysin_NN and_CC tracheal_JJ cytotoxin_NN ._SENT In_IN B._NP bronchiseptica_NP ,_, like_IN in_IN other_JJ members_NNS of_IN the_DT Bordetella_NP genus_NN ,_, a_DT two-component_JJ signal_NN transduction_NN system_NN known_VBN as_IN BvgAS_NP controls_VBZ the_DT expression_NN of_IN all_DT protein_NN virulence_NN factors_NNS that_WDT have_VBP been_VBN identified_VBN ._SENT When_WRB B._NP bronchiseptica_NP grows_VBZ at_IN 37C_JJ in_IN the_DT absence_NN of_IN nicotinic_JJ acid_NN or_CC magnesium_NN sulfate_NN (_( modulating_VBG agents_NNS )_) ,_, it_PP expresses_VBZ the_DT so-called_JJ Bvg-positive_NP (_( Bvg+_NP )_) phase_NN ,_, characterized_VBN by_IN the_DT expression_NN of_IN virulence_NN factors_NNS and_CC the_DT repression_NN of_IN the_DT flagellar_JJ apparatus_NN ,_, among_IN other_JJ Bvg-repressed_JJ phenotypes_NNS ._SENT B._NP bronchiseptica_NP cells_NNS grown_VBN under_IN Bvg+-phase_NP conditions_NNS are_VBP fully_RB virulent_JJ and_CC nonmotile_JJ ._SENT Conversely_RB ,_, incubation_NN below_IN 30C_JJ or_CC addition_NN of_IN modulating_VBG agents_NNS to_TO the_DT culture_NN medium_NN inactivates_VBZ BvgAS_NP ,_, thus_RB simultaneously_RB precluding_VBG protein_NN virulence_NN factor_NN synthesis_NN and_CC derepressing_VBG the_DT flagellar_JJ apparatus_NN and_CC other_JJ Bvg-repressed_JJ phenotypes_NNS ._SENT B._NP bronchiseptica_NP cells_NNS grown_VBN under_IN these_DT conditions_NNS (_( Bvg--phase_NP conditions_NNS )_) are_VBP avirulent_JJ and_CC motile_JJ ._SENT In_IN contrast_NN to_TO this_DT reversible_JJ transition_NN ,_, termed_VBD phenotypic_JJ modulation_NN ,_, mutations_NNS leading_VBG to_TO inactivation_NN of_IN BvgAS_NP result_NN in_IN an_DT irreversible_JJ transition_NN to_TO the_DT Bvg-_NP phase_NN ._SENT Thus_RB ,_, this_DT genetic_JJ event_NN ,_, which_WDT occurs_VBZ at_IN a_DT low_JJ frequency_NN (_( 10-6_CD )_) ,_, gives_VBZ rise_NN to_TO avirulent_JJ Bvg--phase-locked_JJ mutants_NNS ._SENT The_DT existence_NN of_IN a_DT tight_JJ correlation_NN between_IN phenotypic_JJ (_( Bvg_NP )_) phase_NN and_CC virulence_NN has_VBZ received_VBN further_RBR experimental_JJ confirmation_NN with_IN the_DT demonstration_NN that_IN mutants_NNS displaying_VBG phenotypically_RB intermediate_JJ traits_NNS (_( locked_VBN in_IN the_DT so-called_JJ Bvgi_NP phase_NN )_) also_RB exhibit_VB an_DT intermediate_JJ ability_NN to_TO colonize_VB the_DT respiratory_JJ tracts_NNS of_IN suitable_JJ hosts_NNS ._SENT Reports_NNS of_IN respiratory_JJ disease_NN caused_VBN by_IN B._NP bronchiseptica_NN in_IN humans_NNS remain_VBP scarce_JJ and_CC very_RB rarely_RB involve_VB immunocompetent_JJ patients_NNS and_CC more_RBR commonly_RB involve_VB children_NNS and_CC immunocompromised_JJ patients_NNS including_VBG ,_, in_IN many_JJ instances_NNS ,_, AIDS_NP patients_NNS ._SENT For_IN the_DT last_JJ epidemiological_JJ group_NN ,_, isolation_NN of_IN B._NP bronchiseptica_NP from_IN the_DT respiratory_JJ tract_NN or_CC from_IN the_DT blood_NN of_IN human_JJ immunodeficiency_NN virus_NN (HIV)-infected_VBD patients_NNS with_IN respiratory_JJ diseases_NNS has_VBZ been_VBN increasingly_RB reported_VBN ._SENT This_DT circumstance_NN has_VBZ prompted_VBN some_DT investigators_NNS to_TO propose_VB the_DT inclusion_NN of_IN B._NP bronchiseptica_NP in_IN the_DT list_NN of_IN opportunistic_JJ pathogens_NNS causing_VBG diseases_NNS associated_VBN with_IN exposure_NN of_IN HIV-infected_JJ patients_NNS to_TO animals_NNS ._SENT However_RB ,_, thus_RB far_RB the_DT pathogenic_JJ role_NN that_IN B._NP bronchiseptica_NP plays_VBZ in_IN those_DT processes_NNS has_VBZ been_VBN difficult_JJ to_TO ascertain_VB since_IN ,_, in_IN addition_NN to_TO B._NP bronchiseptica_NP ,_, other_JJ respiratory_JJ pathogens_NNS are_VBP usually_RB coisolated_JJ from_IN the_DT respiratory_JJ tracts_NNS of_IN AIDS_NP patients_NNS with_IN pulmonary_JJ infections_NNS ._SENT Finally_RB ,_, to_TO assess_VB the_DT involvement_NN of_IN B._NP bronchiseptica_NN in_IN human_JJ respiratory_JJ diseases_NNS ,_, it_PP seems_VBZ necessary_JJ to_TO determine_VB whether_IN the_DT presence_NN of_IN specific_JJ phenotypic_JJ traits_NNS in_IN certain_JJ B._NP bronchiseptica_NN strains_NNS correlates_NNS with_IN their_PP$ pathogenic_JJ potential_NN ._SENT To_TO our_PP$ knowledge_NN ,_, this_DT kind_NN of_IN information_NN is_VBZ lacking_VBG ._SENT In_IN this_DT article_NN we_PP report_VBP on_IN two_CD cases_NNS of_IN pulmonary_JJ disease_NN in_IN AIDS_NP patients_NNS differing_VBG in_IN severity_NN and_CC clinical_JJ presentation_NN and_CC make_VB an_DT evaluation_NN of_IN the_DT pathogenic_JJ role_NN of_IN B._NP bronchiseptica_NP in_IN the_DT clinical_JJ processes_NNS ._SENT Patient_NN 1_CD ._SENT |_SYM A_DT 34-year-old_JJ woman_NN was_VBD admitted_VBN to_TO the_DT Hospital_NP Universitario_NP Virgen_NP del_NP Rocio_NP reporting_VBG a_DT 2-week_JJ history_NN of_IN cough_NN with_IN purulent_JJ expectoration_NN ,_, fever_NN ,_, and_CC chills_NNS ._SENT In_IN addition_NN ,_, she_PP reported_VBD having_VBG lost_VBN 50_CD %_NN of_IN her_PP$ normal_JJ weight_NN in_IN the_DT previous_JJ 2_CD months_NNS ._SENT Four_CD years_NNS earlier_RBR she_PP had_VBD maintained_VBN frequent_JJ heterosexual_JJ intercourse_NN with_IN an_DT HIV-infected_JJ individual_NN ._SENT At_IN the_DT time_NN of_IN her_PP$ admission_NN ,_, she_PP owned_VBD a_DT healthy_JJ dog_NN ._SENT On_IN examination_NN oropharyngeal_NN thrush_NN was_VBD observed_VBN and_CC rales_NNS in_IN the_DT left_JJ hemithorax_NN were_VBD heard_VBN ._SENT The_DT total_JJ leukocyte_NN count_NN was_VBD 13,100/mul_NP ,_, the_DT hemoglobin_NN concentration_NN was_VBD 9.2_CD g/dl_NN ,_, and_CC the_DT platelet_NN count_NN was_VBD 256,000/mul_JJ ._SENT Serum_NN electrolyte_NN and_CC creatinine_NN levels_NNS and_CC liver_NN enzyme_NN levels_NNS were_VBD in_IN the_DT normal_JJ ranges_NNS ._SENT The_DT arterial_JJ partial_JJ oxygen_NN pressure_NN was_VBD 67_CD mm_NN Hg_NP ,_, the_DT arterial_JJ partial_JJ carbon_NN dioxide_NN pressure_NN was_VBD 39_CD mm_NN Hg_NN ,_, and_CC the_DT pH_NN was_VBD 7.4_CD ._SENT Detection_NN of_IN anti-HIV_NP immunoglobulin_NN G_NN antibodies_NNS first_JJ by_IN enzyme_NN immunoassay_NN and_CC then_RB by_IN Western_JJ immunoblotting_NN confirmed_VBN HIV_NP infection_NN ._SENT The_DT CD4_NP lymphocyte_NN count_NN was_VBD 25/mul_JJ ,_, and_CC HIV_NP RNA_NP levels_NNS were_VBD 1.5_CD x_SYM 106_CD copies/ml_NN ._SENT A_DT chest_NN X_NN ray_NN showed_VBD an_DT alveolar_JJ infiltrate_NN with_IN areas_NNS of_IN cavitation_NN in_IN the_DT left_JJ upper_JJ lung_NN lobe_NN ._SENT Microscopic_JJ examination_NN of_IN sputum_NN smears_NNS stained_VBN with_IN either_DT acid-fast_JJ or_CC Gram_NP stain_NN did_VBD not_RB reveal_VB the_DT presence_NN of_IN any_DT microorganism_NN ._SENT Because_IN of_IN the_DT suspicion_NN of_IN tuberculosis_NN ,_, isoniazid_NN ,_, rifampin_NN ,_, and_CC pyrazinamide_NN were_VBD administered_VBN ._SENT Sputum_NN cultures_NNS exclusively_RB yielded_VBD growth_NN of_IN B._NP bronchiseptica_NN in_IN pure_JJ culture_NN ._SENT This_DT B._NP bronchiseptica_NP clinical_JJ isolate_NN was_VBD designated_VBN 814_CD and_CC was_VBD sensitive_JJ to_TO amikacin_NP (_( MIC_NP ,_, 16_CD mug/ml_NN )_) ,_, amoxicillin-clavulanic_JJ acid_NN (_( MIC_NP ,_, 8/4_CD mug/ml_NN )_) ,_, ciprofloxacin_NP (_( MIC_NP ,_, <1_JJ mug/ml_NN )_) ,_, ofloxacin_NP (_( MIC_NP ,_, <2_JJ mug/ml_NN )_) ,_, gentamicin_NN (_( MIC_NP ,_, 4_CD mug/ml_NN )_) ,_, imipenem_NP (_( MIC_NP ,_, <4_NN mug/ml_NN )_) ,_, tetracycline_NN (_( MIC_NP ,_, <4_NN mug/ml_NN )_) ,_, ticarcillin-clavulanic_JJ acid_NN (_( MIC_NP ,_, <16_mug/ml), 104_CD CFU_NP of_IN B._NP bronchiseptica_NP with_IN the_DT same_JJ antibiotic_JJ sensitivity_NN as_IN the_DT organism_NN recovered_VBD from_IN sputum_NN ._SENT Treatment_NN was_VBD switched_VBN to_TO ofloxacin_NNS (_( 400_CD mg_NN oral_JJ twice_RB a_DT day_NN )_) on_IN the_DT 10th_JJ day_NN ._SENT On_IN the_DT 20th_JJ day_NN the_DT patient_NN was_VBD asymptomatic_JJ ,_, control_NN cultures_NNS of_IN sputum_NN were_VBD negative_JJ ,_, and_CC chest_NN X_NN ray_NN showed_VBD progressive_JJ resolution_NN of_IN the_DT infiltrate_NN ._SENT On_IN the_DT 28th_JJ day_NN ,_, the_DT patient_NN was_VBD discharged_VBN with_IN antiretroviral_JJ therapy_NN consisting_VBG of_IN stavudine_NP ,_, lamivudine_NP ,_, and_CC indinavir_NN ._SENT Antimicrobial_JJ treatment_NN was_VBD maintained_VBN for_IN a_DT total_NN of_IN 4_CD weeks_NNS ._SENT Three_CD months_NNS after_IN admission_NN the_DT patient_NN remained_VBD asymptomatic_JJ ,_, the_DT CD4_NP cell_NN counts_NNS were_VBD 250/mul_JJ ,_, the_DT HIV_NP RNA_NP levels_NNS were_VBD 70,000_CD copies/ml_NN ,_, and_CC a_DT control_NN chest_NN X_NP ray_NN appeared_VBD normal_JJ ._SENT Patient_NN 2_CD ._SENT |_SYM A_DT 26-year-old_JJ man_NN who_WP had_VBD been_VBN diagnosed_VBN with_IN AIDS_NP and_CC who_WP had_VBD had_VBN Pneumocystis_NP carinii_NP pneumonia_NN 2_CD months_NNS earlier_RBR was_VBD admitted_VBN to_TO the_DT Hospital_NP Universitario_NP Virgen_NP del_NP Rocio_NP with_IN a_DT 5-day_JJ history_NN of_IN cough_NN ,_, high_JJ fever_NN ,_, weight_NN loss_NN ,_, and_CC left_VBD costal_JJ pain_NN ._SENT He_PP was_VBD a_DT heroin_NN addict_NN and_CC did_VBD not_RB report_VB any_DT contact_NN with_IN household_NN ,_, farm_NN ,_, or_CC wild_JJ animals_NNS ._SENT The_DT physical_JJ examination_NN disclosed_VBD fever_NN (_( 38.5C_JJ )_) ,_, cachexia_NN ,_, tachypnea_NP ,_, oral_JJ thrush_NN ,_, enlargement_NN of_IN the_DT cervical_JJ lymph_NN nodes_NNS ,_, and_CC middle_JJ hepatomegaly_NN ._SENT The_DT rest_NN of_IN the_DT physical_JJ examination_NN was_VBD unremarkable_JJ ._SENT A_DT chest_NN X_NN ray_NN (_( not_RB shown_VBN )_) revealed_VBD a_DT middle_JJ diffuse_JJ interstitial_JJ infiltrate_NN ._SENT The_DT total_JJ leukocyte_NN count_NN was_VBD 10,500/mul_NP ,_, the_DT hemoglobin_NN concentration_NN was_VBD 10.6_CD g/dl_NN ,_, and_CC the_DT platelet_NN count_NN was_VBD 364,000/mul_JJ ._SENT Serum_NN electrolyte_NN and_CC creatinine_NN levels_NNS and_CC liver_NN enzyme_NN levels_NNS were_VBD in_IN the_DT normal_JJ ranges_NNS ._SENT The_DT arterial_JJ partial_JJ oxygen_NN pressure_NN was_VBD 67_CD mm_NN Hg_NP ,_, the_DT arterial_JJ partial_JJ carbon_NN dioxide_NN pressure_NN was_VBD 39_CD mm_NN Hg_NN ,_, and_CC the_DT pH_NN was_VBD 7.4_CD ._SENT The_DT CD4_NP lymphocyte_NN count_NN was_VBD 97/mul_NN ,_, and_CC the_DT viral_JJ load_NN was_VBD 338,623_CD copies/ml_NN ._SENT Because_IN of_IN the_DT initial_JJ suspicion_NN of_IN P._NP carinii_NP pneumonia_NN ,_, trimethoprim-sulfamethoxazole_NN treatment_NN was_VBD started_VBN and_CC the_DT fever_NN disappeared_VBD ._SENT Later_RBR ,_, in_IN a_DT computed_VBN tomography_NN scan_NN of_IN the_DT thorax_NN ,_, two_CD noncavitating_JJ nodules_NNS <5_cm 104_NP CFU_NP )_) grew_VBD in_IN the_DT samples_NNS obtained_VBN through_IN the_DT protected_JJ brush_NN catheter_NN and_CC bronchoalveolar_NN lavage_NN ._SENT The_DT second_JJ B._NP bronchiseptica_NN isolate_NN recovered_VBN from_IN patient_JJ 2_CD was_VBD designated_VBN 629_CD and_CC was_VBD sensitive_JJ to_TO ciprofloxacin_NP (_( MIC_NP ,_, <1_JJ mug/ml_NN )_) ,_, ofloxacin_NP (_( MIC_NP ,_, <2_JJ mug/ml_NN )_) ,_, amikacin_NP (_( MIC_NP ,_, 16_CD mug/ml_NN )_) ,_, amoxicillin-clavulanic_JJ acid_NN (_( MIC_NP ,_, 8/4_CD mug/ml_NN )_) ,_, gentamicin_NN (_( MIC_NP ,_, 4_CD mug/ml_NN )_) ,_, imipenem_NP (_( MIC_NP ,_, <4_NN mug/ml_NN )_) ,_, tetracycline_NN (_( MIC_NP ,_, <4_NN mug/ml_NN )_) ,_, ticarcillin-clavulanic_JJ acid_NN (_( MIC_NP ,_, <16_NN mug/ml_NN )_) ,_, and_CC tobramycin_NP (_( MIC_NP ,_, 4_CD mug/ml_NN )_) and_CC was_VBD resistant_JJ to_TO co-trimoxazole_VB (_( MIC_NP ,_, 2/38_CD mug/ml_NN )_) ._SENT Trimethoprim-sulfamethoxazole_NP was_VBD discontinued_VBN ;_: and_CC vancomycin_NP ,_, rifampin_NN ,_, and_CC ciprofloxacin_NN were_VBD administered_VBN for_IN 15_CD days_NNS and_CC the_DT patient_NN was_VBD discharged_VBN ._SENT One_CD week_NN before_IN discharge_NN the_DT patient_NN quit_VBD the_DT antimicrobial_JJ treatment_NN ._SENT Two_CD months_NNS later_RBR he_PP was_VBD admitted_VBN to_TO the_DT hospital_NN with_IN fever_NN ,_, cough_NN ,_, and_CC chills_NNS ._SENT Chest_NN X_NN ray_NN and_CC computed_VBN tomography_NN scan_NN images_NNS (_( not_RB shown_VBN )_) showed_VBD multiple_JJ bilateral_JJ nodules_NNS and_CC an_DT infiltrate_NN in_IN the_DT left_RB lower_JJR lung_NN lobe_NN ._SENT R._NP equi_NP was_VBD the_DT only_JJ microorganism_NN isolated_VBN from_IN blood_NN cultures_NNS and_CC samples_NNS obtained_VBN through_IN bronchoscopy_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Chest_NP X_NP ray_NN demonstrates_VBZ cavitary_JJ pneumonia_NN in_IN patient_JJ 1_CD ._SENT Chest_NN X_NN ray_NN demonstrates_VBZ cavitary_JJ pneumonia_NN in_IN patient_JJ 1_CD ._SENT Identification_NN of_IN clinical_JJ isolates_NNS ._SENT |_SYM Isolation_NN of_IN B._NP bronchiseptica_NN from_IN bronchoalveolar_JJ lavage_NN specimens_NNS was_VBD performed_VBN as_RB follows_VBZ ._SENT The_DT bronchoalveolar_JJ lavage_NN fluid_NN was_VBD diluted_VBN 1:10_CD and_CC 1:100_CD prior_JJ to_TO its_PP$ inoculation_NN on_IN enriched_VBN blood_NN and_CC chocolate_NN agar_NN plates_NNS ._SENT Only_RB bronchoalveolar_JJ lavage_NN fluid_NN specimens_NNS rendering_VBG colony_NN counts_NNS of_IN at_IN least_JJS 10,000_CD CFU/ml_NP were_VBD considered_VBN positive_NN and_CC were_VBD further_RBR processed_VBN ._SENT Clinical_JJ isolates_NNS were_VBD identified_VBN as_IN B._NP bronchiseptica_NP by_IN using_VBG combined_JJ sensitivity-identification_NN panels_NNS (_( NEG_NP Breakpoint_NP Combo_NP Type_NP 15_CD ;_: Dade_NP International_NP Inc._NP ,_, West_NP Sacramento_NP ,_, Calif._NP )_) and_CC miniature_JJ bacterial_JJ identification_NN strips_NNS (_( API_NP NE_NP ;_: bio_NP Merieux_NP ,_, Marcy_NP l'Etoile_NP ,_, France_NP )_) ._SENT Microscopic_JJ examination_NN of_IN Gram-stained_JJ smears_NNS ,_, extensive_JJ phenotypic_JJ characterization_NN of_IN the_DT isolates_NNS (_( see_VB Table_NN and_CC Fig._NN and_CC )_) ,_, and_CC DNA_NP sequencing_NP of_IN a_DT portion_NN of_IN the_DT bvgS_NNS gene_NN of_IN isolate_NN 814_CD supported_VBD the_DT identification_NN of_IN the_DT isolates_NNS as_IN B._NP bronchiseptica_NP ._SENT Bacterial_JJ strains_NNS and_CC growth_NN conditions_NNS ._SENT |_SYM B._NP bronchiseptica_NP strains_NNS RB50_NP and_CC RB54_NP were_VBD a_DT kind_NN gift_NN of_IN Peggy_NP Cotter_NP (_( Department_NP of_IN Molecular_NP ,_, Cellular_NP and_CC Developmental_NP Biology_NP ,_, University_NP of_IN California_NP ,_, Santa_NP Barbara_NP )_) ._SENT These_DT are_VBP well-characterized_JJ strains_NNS that_WDT have_VBP been_VBN used_VBN in_IN several_JJ studies_NNS on_IN the_DT interaction_NN of_IN B._NP bronchiseptica_NP with_IN its_PP$ natural_JJ hosts_NNS ._SENT RB50_NP is_VBZ a_DT wild-type_NN strain_NN isolated_VBN from_IN the_DT nares_NN of_IN a_DT naturally_RB infected_JJ rabbit_NN ._SENT RB54_NP is_VBZ a_DT Bvg--phase-locked_JJ derivative_NN of_IN RB50_NP ._SENT As_IN positive_JJ or_CC negative_JJ controls_NNS for_IN some_DT biochemical_JJ determinations_NNS ,_, human_JJ and_CC ovine_JJ isolates_NNS of_IN B._NP parapertussis_NN (_( strains_NNS 12822_CD and_CC Fr107_JJ ,_, respectively_RB )_) were_VBD used_VBN ._SENT For_IN the_DT determination_NN of_IN hemolytic_JJ activity_NN and_CC colony_NN morphology_NN ,_, all_PDT the_DT strains_NNS were_VBD grown_VBN on_IN Bordet-Gengou_NP (_( BG_NP )_) agar_NN plates_NNS supplemented_VBN with_IN 7.5_CD %_NN defibrinated_JJ sheep_NN blood_NN ._SENT The_DT plates_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 48_CD h._JJ Motility_NN assays_NNS were_VBD performed_VBN by_IN stabbing_VBG one_CD medium-size_JJ colony_NN in_IN Stainer-Scholte_NP (_( SS_NP )_) medium_NN supplemented_VBN with_IN 0.35_CD %_NN agar_NN ._SENT The_DT diameter_NN of_IN the_DT motility_NN halo_NN was_VBD measured_VBN after_IN 14_CD h_NN of_IN incubation_NN at_IN 37C_JJ ._SENT When_WRB it_PP was_VBD necessary_JJ to_TO grow_VB Bordetella_NP under_IN Bvg--phase_NP (_( modulating_VBG )_) conditions_NNS ,_, nicotinic_JJ acid_NN and_CC MgSO4_NP were_VBD added_VBN to_TO the_DT medium_NN at_IN final_JJ concentrations_NNS of_IN 5_CD and_CC 20_CD mM_NNS ,_, respectively_RB ._SENT Tyrosine_NN agar_NN plates_NNS for_IN determination_NN of_IN the_DT browning_VBG activities_NNS of_IN the_DT strains_NNS were_VBD prepared_VBN as_IN described_VBN by_IN Porter_NP et_FW al._FW ._SENT Whole-cell_NN lysates_NNS for_IN sodium_NN dodecyl_NN sulfate_NN (SDS)-polyacrylamide_NN gel_NN electrophoresis_NN (_( PAGE_NP )_) analysis_NN were_VBD prepared_VBN from_IN cells_NNS grown_VBN overnight_RB in_IN Luria-Bertani_NP (_( LB_NP )_) broth_NN at_IN 37C_JJ with_IN constant_JJ shaking_VBG ._SENT To_TO ensure_VB the_DT absence_NN of_IN Bvg--phase_NP mutants_NNS in_IN the_DT liquid_JJ cultures_NNS ,_, an_DT aliquot_NN of_IN each_DT culture_NN was_VBD plated_VBN on_IN BG_NP blood_NN agar_NN ,_, and_CC after_IN 48_CD h_NN of_IN incubation_NN at_IN 37C_NP ,_, the_DT colonies_NNS were_VBD visually_RB inspected_VBN for_IN hemolytic_JJ activity_NN ._SENT SDS-PAGE_NP ,_, Western_JJ immunoblotting_NN ,_, and_CC densitometry_NN ._SENT |_SYM SDS-PAGE_NP was_VBD performed_VBN as_IN described_VBN previously_RB ._SENT Briefly_RB ,_, bacterial_JJ cells_NNS suspended_VBN in_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) were_VBD lysed_VBN by_IN the_DT addition_NN of_IN 2x_NP SDS-PAGE_NP sample_NN buffer_NN ._SENT Bacterial_JJ lysates_NNS were_VBD boiled_VBN for_IN 5_CD min_NN ,_, stacked_VBN in_IN an_DT SDS-4_NP %_NN polyacrylamide_NN gel_NN ,_, and_CC separated_VBN in_IN an_DT SDS-10_NP %_NN polyacrylamide_NN gel_NN ._SENT Proteins_NNS were_VBD stained_VBN with_IN Coomassie_NP brilliant_JJ blue_NN or_CC transferred_VBN to_TO polyvinylidene_JJ difluoride_NN membranes_NNS for_IN immunoblotting_NN ._SENT Proteins_NNS were_VBD probed_VBN with_IN either_CC a_DT 1:16,000_CD dilution_NN of_IN serum_NN from_IN a_DT rat_NN infected_VBN with_IN B._NP bronchiseptica_NP RB50_NP (_( RA1_NP antiserum_NN )_) ,_, a_DT 1:2,500_CD dilution_NN of_IN antipertactin_NN monoclonal_NN antibody_NN (_( MAb_NP )_) BPE3_NP ,_, or_CC a_DT 1:2,000_CD dilution_NN of_IN serum_NN from_IN rats_NNS infected_VBN with_IN either_RB one_CD of_IN the_DT clinical_JJ isolates_NNS ._SENT Antigen-antibody_NN complexes_NNS were_VBD detected_VBN with_IN a_DT 1:5,000_CD dilution_NN of_IN horseradish_NN peroxidase-conjugated_JJ antibody_NN of_IN the_DT appropriate_JJ specificity_NN (_( Amersham_NP International_NP ,_, Little_NP Chalfont_NP ,_, United_NP Kingdom_NP )_) ._SENT The_DT immunocomplexes_NNS were_VBD detected_VBN by_IN using_VBG an_DT enhanced_JJ chemiluminescence_NN assay_NN (_( Amersham_NP )_) according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT Densitometric_JJ analysis_NN was_VBD carried_VBN out_RP on_IN digitized_VBN images_NNS obtained_VBN with_IN a_DT high-resolution_NN scanner_NN (_( JX_NP 325_CD ;_: Sharp_NP Corporation_NP ,_, Osaka_NP ,_, Japan_NP )_) equipped_VBD with_IN Amersham_NP Pharmacia_NP ImageMaster_NP software_NN ._SENT Experimental_JJ animals_NNS ._SENT |_SYM Female_NP Wistar_NP rats_NNS were_VBD obtained_VBN from_IN Harlan_NP Spain_NP (_( Harlan_NP Interfauna_NP Iberica_NP S.A._NP ,_, Barcelona_NP ,_, Spain_NP )_) at_IN 3_CD weeks_NNS of_IN age_NN ._SENT To_TO confirm_VB that_IN they_PP were_VBD Bordetella-free_JJ ,_, two_CD animals_NNS of_IN each_DT lot_NN were_VBD euthanatized_JJ and_CC samples_NNS of_IN nasal_JJ ,_, tracheal_JJ ,_, and_CC lung_NN tissue_NN were_VBD removed_VBN and_CC cultured_VBN on_IN BG_NP blood_NN agar_NN ._SENT Inocula_NNS were_VBD prepared_VBN from_IN cells_NNS grown_VBN overnight_RB in_IN LB_NP broth_NN and_CC consisted_VBD of_IN 1,000_CD CFU_NP administered_VBN intranasally_RB in_IN 10_CD mul_NN of_IN PBS_NP while_IN the_DT animals_NNS were_VBD slightly_RB anesthetized_VBN by_IN halothane_NN inhalation_NN ._SENT At_IN the_DT designated_VBN time_NN points_NNS postinoculation_NN ,_, the_DT rats_NNS were_VBD anesthetized_VBN by_IN halothane_NN inhalation_NN ,_, a_DT sample_NN of_IN blood_NN was_VBD obtained_VBN by_IN cardiac_JJ puncture_NN ,_, and_CC then_RB the_DT animals_NNS were_VBD killed_VBN by_IN cervical_JJ dislocation_NN ._SENT The_DT chest_NN cavity_NN was_VBD opened_VBN ,_, and_CC 1_CD cm_NN of_IN trachea_NN and_CC the_DT right_JJ lung_NN lobes_NNS were_VBD removed_VBN and_CC placed_VBN in_IN PBS_NP for_IN homogenization_NN ._SENT The_DT nose_NN was_VBD dissected_VBN ,_, and_CC the_DT entire_JJ nasal_JJ septum_NN and_CC the_DT adjacent_JJ tissues_NNS were_VBD removed_VBN and_CC placed_VBN in_IN PBS_NP ._SENT Tissues_NNS were_VBD homogenized_VBN with_IN tissue_NN grinders_NNS ,_, and_CC aliquots_NNS of_IN the_DT suspensions_NNS were_VBD plated_VBN on_IN BG_NP blood_NN agar_NN for_IN determination_NN of_IN viable_JJ counts_NNS ._SENT Experimental_JJ data_NNS were_VBD analyzed_VBN by_IN a_DT two-way_JJ analysis_NN of_IN variance_NN test_NN with_IN SPSS_NP software_NN ._SENT Prior_RB to_TO this_DT analysis_NN ,_, the_DT interaction_NN between_IN the_DT parameters_NNS under_IN investigation_NN (_( animals_NNS of_IN each_DT group_NN ,_, strain_NN type_NN ,_, site_NN of_IN the_DT respiratory_JJ tract_NN )_) was_VBD confirmed_VBN to_TO be_VB nonsignificant_JJ ._SENT Animal_NN protocols_NNS were_VBD approved_VBN by_IN the_DT University_NP of_IN Navarra_NP Animal_NP Research_NP Committee_NP (_( protocol_NN number_NN 039/00_CD )_) ._SENT Hemagglutination_NP and_CC ELISAs_NP ._SENT |_SYM Hemagglutination_NP activity_NN was_VBD quantitated_VBN in_IN the_DT supernatants_NNS of_IN cultures_NNS grown_VBN in_IN SS_NP medium_NN for_IN 24_CD h_NN at_IN 37C_JJ with_IN constant_JJ shaking_VBG ._SENT The_DT hemagglutination_NN assay_NN has_VBZ already_RB been_VBN described_VBN ._SENT Enzyme-linked_JJ immunosorbent_JJ assays_NNS (_( ELISAs_NP )_) were_VBD performed_VBN as_IN described_VBN by_IN Cotter_NP and_CC Miller_NP with_IN slight_JJ modifications_NNS ._SENT Briefly_RB ,_, an_DT overnight_JJ culture_NN of_IN each_DT B._NP bronchiseptica_NN strain_NN was_VBD adjusted_VBN to_TO an_DT optical_JJ density_NN (_( 600_CD nm_NN )_) of_IN 1.0_CD with_IN LB_NP broth_NN ,_, and_CC the_DT suspensions_NNS were_VBD diluted_VBN 1:10_CD in_IN coating_NN buffer_NN (_( carbonate-bicarbonate_JJ buffer_NN [_SYM pH_NN 9.7_CD ]_SYM )_) and_CC sonicated_JJ ._SENT A_DT total_NN of_IN 100_CD mul_NN of_IN the_DT suspension_NN was_VBD added_VBN to_TO each_DT well_NN ,_, and_CC the_DT plates_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 2_CD h_NN in_IN a_DT humidified_VBN chamber_NN and_CC then_RB overnight_JJ at_IN 4C_JJ ._SENT Nonspecific_JJ binding_NN to_TO the_DT wells_NNS was_VBD prevented_VBN by_IN adding_VBG 150_CD mul_NN of_IN 3_CD %_NN bovine_JJ serum_NN albumin_NN to_TO each_DT well_RB and_CC incubating_VBG the_DT plate_NN for_IN 60_CD min_NN at_IN 37C_JJ ._SENT As_IN the_DT primary_JJ antibody_NN ,_, a_DT 1:6,000_CD dilution_NN of_IN RA1_NP antiserum_NN was_VBD added_VBN to_TO the_DT first_JJ well_NN ,_, twofold_JJ dilutions_NNS were_VBD performed_VBN across_IN eight_CD wells_NNS ,_, and_CC the_DT plates_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 60_CD min_NN ._SENT As_IN the_DT secondary_JJ antibody_NN ,_, horseradish_NN peroxidase-conjugated_JJ anti-rat_NN immunoglobulin_NN G_NP antibody_NN (_( Amersham_NP )_) was_VBD used_VBN at_IN a_DT final_JJ concentration_NN of_IN 1:5,000_CD ._SENT The_DT A405_NP was_VBD read_VBN after_IN a_DT 30-min_JJ incubation_NN with_IN the_DT substrate_NN 2,2'-azinobis(3'-ethylbenzthiazoline_JJ sulfonic_JJ acid_NN )_) ,_, purchased_VBN from_IN Sigma_NP ._SENT PCR_NP ,_, cloning_VBG ,_, and_CC sequencing_NP ._SENT |_SYM Two_NP oligonucleotides_NNS designed_VBN to_TO anneal_VB at_IN positions_NNS 2556_CD (_( GCTGGAATTCATGCGCGTGCTCA_NP )_) and_CC 3145_CD (_( CGATCTTCGCAATGTCCAG_NP )_) ,_, respectively_RB ,_, of_IN the_DT published_JJ B._NP bronchiseptica_NN bvgAS_NNS sequence_NN were_VBD used_VBN as_IN primers_NNS for_IN the_DT PCR_NP ._SENT PCR_NP was_VBD performed_VBN as_RB follows_VBZ :_: 3_CD mM_NP MgCl2_NP ,_, 5_CD %_NN dimethyl_NN sulfoxide_NN ,_, 1_CD U_NP of_IN Taq_NP polymerase_NN (_( Perkin-Elmer_NP ,_, Wellesley_NP ,_, Mass._NP )_) ,_, the_DT four_CD deoxynucleoside_NN triphosphates_NNS each_DT at_IN a_DT concentration_NN of_IN 250_CD muM_NN ,_, and_CC 20_CD pmol_NN of_IN each_DT primer_NN were_VBD combined_VBN and_CC brought_VBN to_TO a_DT total_JJ volume_NN of_IN 25_CD mul_NN ._SENT A_DT small_JJ portion_NN of_IN a_DT colony_NN was_VBD resuspended_VBN in_IN the_DT solution_NN as_IN a_DT source_NN of_IN template_NN DNA_NN ._SENT A_DT Perkin-Elmer_NP GeneAmp_NP 2400_CD thermal_JJ cycler_NN was_VBD used_VBN for_IN the_DT reactions_NNS ._SENT The_DT cycling_NN parameters_NNS were_VBD as_RB follows_VBZ :_: incubation_NN at_IN 95C_NN for_IN 5_CD min_NN ,_, followed_VBN by_IN 30_CD cycles_NNS of_IN 95C_NN for_IN 1_CD min_NN ,_, 55C_NN for_IN 1_CD min_NN ,_, and_CC 72C_NP for_IN 1_CD min_NN and_CC a_DT final_JJ incubation_NN at_IN 72C_NP for_IN 5_CD min_NN ._SENT PCR_NP products_NNS were_VBD cloned_VBN into_IN the_DT pCR2.1_JJ vector_NN by_IN using_VBG the_DT TA_NP cloning_VBG kit_NN (_( Invitrogen_NP ,_, Carlsbad_NP ,_, Calif._NP )_) according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT Plasmids_NNS containing_VBG the_DT cloned_VBN PCR_NP products_NNS were_VBD submitted_VBN for_IN sequencing_VBG to_TO Sistemas_NP Genomicos_NP ,_, S.L._NP (_( Paterna_NP ,_, Spain_NP )_) ._SENT Construction_NN of_IN mutant_JJ strains_NNS by_IN allelic_JJ exchange_NN ._SENT |_SYM The_DT construction_NN and_CC characteristics_NNS of_IN plasmid_NP PGMT8_NP have_VBP already_RB been_VBN described_VBN ._SENT The_DT entire_JJ bvgAS_NN locus_NN of_IN B._NP bronchiseptica_NP 814_CD and_CC adjacent_JJ sequences_NNS were_VBD deleted_VBN by_IN allelic_JJ exchange_NN with_IN plasmid_NP pGMT8_NN to_TO generate_VB strain_NN B._NP bronchiseptica_NP 814-DAS_NP ._SENT B._NP bronchiseptica_NP 814-DAS_JJ shares_NNS with_IN RB55_NP the_DT genetic_JJ configuration_NN at_IN that_DT chromosomal_JJ location_NN and_CC was_VBD constructed_VBN by_IN the_DT same_JJ method_NN ._SENT PCR_NP analysis_NN with_IN primers_NNS designed_VBN to_TO anneal_VB at_IN both_DT sides_NNS of_IN the_DT deletion_NN junction_NN resulted_VBN in_IN the_DT amplification_NN of_IN a_DT fragment_NN with_IN the_DT expected_VBN size_NN ,_, thus_RB confirming_VBG that_DT allelic_JJ exchange_NN had_VBD occurred_VBN as_IN intended_VBN ._SENT Plasmid_NP pGMT40_NP carries_VBZ a_DT chimeric_JJ bvgAS_NN locus_NN consisting_VBG of_IN the_DT whole_JJ bvgAS_NN locus_NN from_IN B._NP bronchiseptica_NP RB50_NP except_IN for_IN the_DT portion_NN encoding_VBG part_NN of_IN the_DT periplasmic_JJ BvgS_NP domain_NN ._SENT This_DT fragment_NN was_VBD swapped_VBN with_IN the_DT equivalent_JJ segment_NN from_IN B._NP pertussis_NN ,_, and_CC the_DT resultant_JJ allele_NN was_VBD shown_VBN to_TO confer_VB resistance_NN to_TO phenotypic_JJ modulation_NN to_TO B._NP bronchiseptica_NP ._SENT Plasmid_NP pGMT40_NP was_VBD used_VBN to_TO return_VB a_DT wild-type_NN bvgAS_NNS locus_NN to_TO strain_VB B._NP bronchiseptica_NP 814-DAS_NP to_TO generate_VB B._NP bronchiseptica_NNS 814-P5_JJ ._SENT This_DT strain_NN is_VBZ equivalent_JJ to_TO RB52-P5_NP and_CC was_VBD constructed_VBN by_IN the_DT same_JJ method_NN ._SENT Construction_NN of_IN strains_NNS carrying_VBG lacZ_NN fusions_NNS and_CC quantitation_NN of_IN beta-galactosidase_NN activity_NN ._SENT |_SYM Plasmid_NP pGMT18_NN carries_VBZ an_DT internal_JJ fragment_NN of_IN the_DT pertactin_NN gene_NN (_( prn_NN )_) cloned_VBN upstream_RB of_IN a_DT promoterless_JJ lacZ_NN gene_NN ._SENT Its_PP$ integration_NN into_IN the_DT chromosome_NN of_IN Bordetella_NP places_VBZ the_DT transcription_NN of_IN lacZ_NN under_IN the_DT control_NN of_IN the_DT prn_NN promoter_NN ._SENT B._NP bronchiseptica_NP strains_NNS carrying_VBG transcriptional_JJ fusions_NNS to_TO prn_NN were_VBD constructed_VBN by_IN using_VBG pGMT18_NN and_CC by_IN following_VBG a_DT method_NN that_WDT has_VBZ been_VBN already_RB described_VBN ._SENT Beta-galactosidase_NN activity_NN was_VBD measured_VBN as_IN described_VBN previously_RB in_IN cells_NNS grown_VBN in_IN SS_NP medium_NN to_TO the_DT mid-log_NN phase_NN ._SENT Statistical_JJ significance_NN was_VBD determined_VBN by_IN using_VBG the_DT Mann-Whitney_NP test_NN ._SENT To_TO detect_VB the_DT occurrence_NN of_IN spontaneous_JJ bvgAS_NNS mutants_NNS ,_, aliquots_NNS from_IN each_DT broth_NN with_IN growth_NN were_VBD plated_VBN onto_IN BG_NP blood_NN agar_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Analysis_NN of_IN polypeptide_NN and_CC antigen_NN expression_NN in_IN whole_JJ cells_NNS of_IN the_DT B._NP bronchiseptica_NN Analysis_NN of_IN polypeptide_NN and_CC antigen_NN expression_NN in_IN whole_JJ cells_NNS of_IN the_DT B._NP bronchiseptica_NP clinical_JJ isolates_NNS ._SENT (_( A_NP and_CC B_NP )_) Whole-cell_NN lysates_NNS of_IN the_DT indicated_JJ strains_NNS were_VBD run_VBN in_IN duplicate_JJ SDS-polyacrylamide_NN gels_NNS and_CC either_RB stained_VBN with_IN Coomassie_NP brilliant_JJ blue_NN (_( A_NP )_) or_CC transferred_VBN to_TO polyvinylidene_JJ difluoride_NN membranes_NNS for_IN immunoblotting_NN and_CC probed_VBN with_IN serum_NN from_IN a_DT rat_NN infected_VBN with_IN B._NP bronchiseptica_NP RB50_NP (_( B_NP )_) ._SENT The_DT positions_NNS of_IN the_DT molecular_JJ weight_NN markers_NNS (_( in_IN thousands_NNS )_) are_VBP shown_VBN at_IN the_DT left_NN ._SENT (_( C_NP )_) Quantitation_NN of_IN total_JJ antigen_NN expression_NN by_IN a_DT whole-cell_NN antigen-based_JJ ELISA_NP ._SENT The_DT same_JJ serum_NN sample_NN used_VBN for_IN panel_NN B_NN was_VBD used_VBN as_IN the_DT primary_JJ antibody_NN ._SENT FIG._NN 4_CD ._SENT |_SYM Expression_NN of_IN pertactin_NN in_IN whole_JJ cells_NNS of_IN the_DT B._NP bronchiseptica_NN Expression_NN of_IN pertactin_NN in_IN whole_JJ cells_NNS of_IN the_DT B._NP bronchiseptica_NP clinical_JJ isolates_NNS ._SENT Whole-cell_NN lysates_NNS of_IN the_DT indicated_JJ strains_NNS were_VBD run_VBN in_IN duplicate_JJ SDS-polyacrylamide_NN gels_NNS and_CC either_RB stained_VBN with_IN Coomassie_NP brilliant_JJ blue_NN (_( A_NP )_) or_CC transferred_VBN to_TO polyvinylidene_JJ difluoride_NN membranes_NNS for_IN immunoblotting_NN and_CC probed_VBN with_IN antipertactin_NP MAb_NP BPE3_NP (_( B_NP )_) ._SENT Band_NN sizes_NNS were_VBD determined_VBN by_IN densitometry_NN and_CC are_VBP expressed_VBN in_IN units_NNS of_IN optical_JJ density_NN millimeter-2_NN with_IN respect_NN to_TO a_DT calibrated_VBN standard_NN ._SENT The_DT positions_NNS of_IN the_DT molecular_JJ weight_NN markers_NNS (_( in_IN thousands_NNS )_) are_VBP shown_VBN at_IN the_DT left_NN ._SENT TABLE_NN 1_CD |_SYM Relevant_JJ phenotypes_NNS of_IN the_DT strains_NNS used_VBN in_IN this_DT study_NN Rationale_NN for_IN the_DT study_NN and_CC phenotypic_JJ analysis_NN of_IN the_DT clinical_JJ isolates_NNS ._SENT |_SYM Compared_VBN to_TO patient_NN 2_CD ,_, patient_JJ 1_CD 's_POS respiratory_JJ illness_NN was_VBD more_RBR severe_JJ and_CC could_MD be_VB attributed_VBN solely_RB to_TO infection_NN with_IN B._NP bronchiseptica_NP isolate_NN 814_CD ,_, the_DT only_JJ microorganism_NN isolated_VBN from_IN the_DT respiratory_JJ tract_NN of_IN patient_JJ 1_CD ._SENT Since_IN both_CC the_DT AIDS_NP clinical_JJ stage_NN and_CC the_DT immunological_JJ status_NN of_IN patient_JJ 2_CD did_VBD not_RB significantly_RB differ_VB from_IN those_DT of_IN patient_JJ 1_CD ,_, we_PP hypothesized_VBD that_IN B._NP bronchiseptica_NP 814_CD might_MD be_VB more_RBR pathogenic_JJ than_IN other_JJ B._NP bronchiseptica_NN isolates_VBZ including_VBG those_DT recovered_VBN from_IN patient_NN 2_CD (_( isolates_VBZ 222_CD and_CC 629_CD )_) ._SENT To_TO address_VB this_DT hypothesis_NN ,_, we_PP performed_VBD a_DT comparative_JJ study_NN of_IN selected_JJ phenotypic_JJ characteristics_NNS of_IN these_DT three_CD isolates_NNS ._SENT Specifically_RB ,_, we_PP focused_VBD on_IN those_DT phenotypes_NNS that_WDT are_VBP known_VBN to_TO affect_VB the_DT pathogenic_JJ potential_NN of_IN B._NP bronchiseptica_NP ._SENT Bearing_VBG in_IN mind_NN that_IN the_DT phenotypic_JJ phase_NN of_IN B._NP bronchiseptica_NP closely_RB correlates_VBZ with_IN its_PP$ virulence_NN ,_, we_PP first_RB examined_VBD whether_IN all_PDT the_DT clinical_JJ isolates_NNS were_VBD phenotypically_RB wild-type_JJ (_( virulent_JJ )_) or_CC avirulent_JJ (_( bvg_NN )_) variants_NNS ._SENT Wild-type_NN strains_NNS ,_, like_IN B._NP bronchiseptica_NP RB50_NP ,_, grown_VBN on_IN BG_NP blood_NN agar_NN without_IN modulating_VBG agents_NNS give_VB rise_NN to_TO small_JJ ,_, domed_VBD ,_, and_CC hemolytic_JJ colonies_NNS ,_, while_IN those_DT of_IN Bvgi-phase-locked_JJ mutants_NNS are_VBP slightly_RB larger_JJR ,_, flatter_JJR ,_, and_CC less_RBR hemolytic_JJ ._SENT When_WRB modulating_VBG agents_NNS are_VBP added_VBN to_TO the_DT medium_NN or_CC when_WRB Bvg_NP is_VBZ not_RB functional_JJ (_( i.e._FW ,_, Bvg--phase-locked_JJ mutants_NNS like_IN B._NP bronchiseptica_NP RB54_NP )_) colonies_NNS appear_VBP large_JJ ,_, flat_JJ ,_, and_CC nonhemolytic_JJ ._SENT As_IN shown_VBN in_IN Table_NP ,_, all_DT B._NP bronchiseptica_NP clinical_JJ isolates_NNS were_VBD phenotypically_RB wild_JJ type_NN with_IN respect_NN to_TO colony_NN morphology_NN and_CC hemolysis_NNS ._SENT The_DT ability_NN to_TO regulate_VB another_DT prominent_JJ phenotype_NN ,_, motility_NN ,_, has_VBZ been_VBN shown_VBN to_TO be_VB of_IN major_JJ importance_NN for_IN the_DT pathogenicity_NN of_IN B._NP bronchiseptica_NP ._SENT Thus_RB ,_, mutants_NNS that_WDT cannot_MD repress_VB the_DT flagellar_JJ apparatus_NN in_IN the_DT Bvg+_NP phase_NN are_VBP unable_JJ to_TO colonize_VB the_DT lower_JJR respiratory_JJ tracts_NNS of_IN rats_NNS ._SENT To_TO determine_VB whether_IN any_DT of_IN the_DT clinical_JJ isolates_NNS had_VBD an_DT altered_JJ pattern_NN of_IN regulation_NN of_IN motility_NN ,_, all_RB of_IN the_DT isolates_NNS were_VBD grown_VBN in_IN SS_NP medium_NN with_IN or_CC without_IN modulating_VBG agents_NNS ._SENT As_IN shown_VBN in_IN Table_NP ,_, all_PDT the_DT clinical_JJ isolates_NNS exhibited_VBD a_DT pattern_NN of_IN regulation_NN of_IN motility_NN expected_VBN of_IN a_DT wild-type_JJ B._NP bronchiseptica_NN strain_NN ._SENT Experimental_JJ respiratory_JJ infection_NN of_IN rats_NNS ._SENT |_SYM The_DT ability_NN of_IN B._NP bronchiseptica_NP to_TO colonize_VB the_DT respiratory_JJ tracts_NNS of_IN susceptible_JJ laboratory_NN animals_NNS such_JJ as_IN mice_NNS ,_, rats_NNS ,_, and_CC rabbits_NNS has_VBZ been_VBN successfully_RB exploited_VBN to_TO compare_VB the_DT pathogenic_JJ potentials_NNS of_IN B._NP bronchiseptica_NP strains_NNS in_IN the_DT context_NN of_IN a_DT natural_JJ host-pathogen_NN interaction_NN ._SENT When_WRB delivered_VBN intranasally_RB in_IN a_DT low-volume_JJ (_( 5-_CD to_TO 10-mul_NP )_) droplet_NN of_IN PBS_NP ,_, wild-type_NP B._NP bronchiseptica_NN strains_NNS like_IN RB50_NP efficiently_RB colonize_VB the_DT rat_NN and_CC are_VBP recovered_VBN in_IN high_JJ numbers_NNS from_IN the_DT nose_NN and_CC the_DT trachea_NN and_CC less_RBR consistently_RB from_IN the_DT lungs_NNS of_IN the_DT animal_NN by_IN day_NN 14_CD ._SENT A_DT strong_JJ anti-Bordetella_NN antibody_NN response_NN is_VBZ readily_RB detectable_JJ by_IN day_NN 10_CD ._SENT In_IN sharp_JJ contrast_NN ,_, avirulent_JJ mutants_NNS like_IN RB54_NP are_VBP unable_JJ to_TO colonize_VB any_DT site_NN of_IN the_DT respiratory_JJ tract_NN even_RB at_IN the_DT earliest_JJS time_NN points_NNS tested_VBD ,_, while_IN other_JJ mutants_NNS carrying_VBG less_CC impairing_VBG mutations_NNS display_VBP an_DT intermediate_JJ level_NN of_IN virulence_NN and_CC are_VBP characteristically_RB unable_JJ to_TO colonize_VB the_DT lower_RBR respiratory_JJ tract_NN ._SENT We_PP chose_VBD to_TO use_VB the_DT rat_NN model_NN of_IN respiratory_JJ infection_NN to_TO detect_VB potential_JJ differences_NNS in_IN virulence_NN among_IN the_DT clinical_JJ isolates_NNS ._SENT As_IN expected_VBN ,_, at_IN day_NN 7_CD postinoculation_NN RB54_NP was_VBD not_RB recovered_VBN from_IN the_DT respiratory_JJ tract_NN of_IN any_DT rat_NN ._SENT In_IN contrast_NN ,_, isolates_VBZ 222_CD and_CC 814_CD colonized_VBD the_DT noses_NNS of_IN all_DT animals_NNS at_IN a_DT very_RB similar_JJ level_NN and_CC were_VBD recovered_VBN in_IN similar_JJ numbers_NNS from_IN the_DT lungs_NNS of_IN two_CD of_IN five_CD animals_NNS ._SENT However_RB ,_, compared_VBN to_TO isolate_VB 222_CD ,_, isolate_NN 814_CD showed_VBD a_DT reduced_VBN ability_NN to_TO colonize_VB the_DT tracheas_NNS of_IN the_DT rats_NNS at_IN day_NN 7_CD postinoculation_NN ._SENT This_DT defect_NN was_VBD transient_JJ since_IN at_IN day_NN 14_CD postinoculation_NN this_DT isolate_NN was_VBD capable_JJ of_IN establishing_VBG tracheal_JJ colonization_NN at_IN a_DT level_NN indistinguishable_JJ from_IN those_DT of_IN the_DT other_JJ isolates_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Animals_NNS mock_VBP infected_VBN only_RB with_IN PBS_NP remained_VBD Bordetella-free_NP throughout_IN the_DT experiment_NN ,_, and_CC isolate_VBP 629_CD was_VBD recovered_VBN from_IN all_DT sites_NNS of_IN the_DT respiratory_JJ tract_NN in_IN numbers_NNS similar_JJ to_TO those_DT for_IN isolate_NN 222_CD and_CC strain_NN RB50_NN (_( data_NNS not_RB shown_VBN )_) ._SENT We_PP did_VBD not_RB detect_VB any_DT macroscopic_JJ lesions_NNS in_IN the_DT respiratory_JJ tracts_NNS of_IN the_DT animals_NNS or_CC any_DT outward_JJ sign_NN of_IN respiratory_JJ disease_NN at_IN any_DT time_NN during_IN the_DT course_NN of_IN the_DT infection_NN ._SENT Quantification_NN of_IN FHA_NP production_NN by_IN the_DT clinical_JJ isolates_NNS ._SENT |_SYM A_DT derivative_NN of_IN strain_NN RB50_NP carrying_VBG an_DT in-frame_JJ deletion_NN in_IN the_DT gene_NN encoding_VBG FHA_NP has_VBZ been_VBN shown_VBN to_TO be_VB unable_JJ to_TO colonize_VB the_DT lower_RBR respiratory_JJ tract_NN of_IN rats_NNS ._SENT Therefore_RB ,_, the_DT reduced_VBN ability_NN of_IN isolate_NN 814_CD to_TO colonize_VB the_DT trachea_NN of_IN rats_NNS could_MD be_VB the_DT result_NN of_IN a_DT mutation_NN leading_VBG to_TO the_DT deficient_JJ production_NN or_CC secretion_NN of_IN FHA_NP ._SENT To_TO test_VB this_DT possibility_NN ,_, the_DT amount_NN of_IN FHA_NP in_IN the_DT supernatants_NNS of_IN overnight_JJ cultures_NNS of_IN the_DT isolates_NNS was_VBD measured_VBN ._SENT As_IN shown_VBN in_IN Table_NP ,_, all_DT clinical_JJ isolates_NNS produced_VBD FHA_NP at_IN levels_NNS that_WDT were_VBD identical_JJ to_TO those_DT produced_VBN by_IN RB50_NP ._SENT Characterization_NN of_IN clinical_JJ isolates_NNS by_IN SDS-PAGE_NP and_CC Western_JJ immunoblotting_NN ._SENT |_SYM To_TO determine_VB if_IN the_DT defect_NN in_IN colonization_NN exhibited_VBN by_IN isolate_NN 814_CD could_MD result_VB from_IN the_DT loss_NN of_IN potentially_RB antigenic_JJ virulence_NN determinants_NNS ,_, we_PP compared_VBD the_DT antigenic_JJ profiles_NNS of_IN all_PDT the_DT isolates_NNS by_IN Western_JJ immunoblotting_NN using_VBG serum_NN from_IN a_DT rat_NN infected_VBN with_IN B._NP bronchiseptica_NP RB50_NP (_( RA1_NP antiserum_NN )_) ._SENT As_IN shown_VBN in_IN Fig._NN ,_, while_IN the_DT antigenic_JJ patterns_NNS of_IN isolates_NNS 222_CD and_CC 629_CD were_VBD nearly_RB identical_JJ to_TO that_DT of_IN RB50_NP ,_, isolate_NN 814_CD appeared_VBD to_TO produce_VB background_NN levels_NNS of_IN a_DT large_JJ number_NN of_IN antigens_NNS ._SENT This_DT result_NN was_VBD so_RB striking_JJ that_IN we_PP performed_VBD several_JJ control_NN experiments_NNS to_TO rule_VB out_RP any_DT possible_JJ experimental_JJ error_NN ._SENT Thus_RB ,_, a_DT second_JJ Western_JJ blot_NN analysis_NN with_IN a_DT new_JJ whole-cell_NN extract_NN of_IN isolate_NN 814_CD gave_VBD similar_JJ results_NNS ._SENT In_IN addition_NN ,_, a_DT duplicate_JJ gel_NN was_VBD simultaneously_RB run_VBN and_CC subjected_VBN to_TO Coomassie_NP brilliant_JJ blue_NN staining_VBG to_TO ensure_VB that_IN equivalent_JJ amounts_NNS of_IN protein_NN had_VBD been_VBN loaded_VBN in_IN all_PDT the_DT gel_NN lanes_NNS ._SENT Since_IN the_DT polypeptide_NN profiles_NNS of_IN all_PDT the_DT isolates_NNS were_VBD almost_RB indistinguishable_JJ ,_, the_DT last_JJ experiment_NN also_RB indicated_VBD that_IN the_DT difference_NN in_IN antigenic_JJ profiles_NNS detected_VBN by_IN Western_JJ immunoblotting_NN was_VBD not_RB due_JJ to_TO a_DT global_JJ deficiency_NN in_IN protein_NN expression_NN ._SENT Finally_RB ,_, to_TO rule_VB out_RP potential_JJ experimental_JJ artifacts_NNS derived_VBN from_IN the_DT gel_NN transfer_NN process_NN ,_, we_PP performed_VBD ELISAs_NNS using_VBG whole_JJ cells_NNS as_IN the_DT antigen_NN and_CC RA1_JJ antiserum_NN as_IN the_DT primary_JJ antibody_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, isolate_VBP 814_CD produced_VBN background_NN levels_NNS of_IN the_DT set_NN of_IN antigens_NNS detected_VBN by_IN RA1_JJ antiserum_NN ._SENT Isolate_NN 814_CD expresses_VBZ reduced_VBN levels_NNS of_IN pertactin_NN ._SENT |_SYM Due_JJ to_TO the_DT limited_JJ genetic_JJ diversity_NN of_IN B._NP bronchiseptica_NP ,_, it_PP is_VBZ highly_RB unlikely_JJ that_IN an_DT antiserum_NN raised_VBN against_IN a_DT certain_JJ isolate_NN will_MD not_RB show_VB strong_JJ cross-reactivity_NN when_WRB it_PP is_VBZ used_VBN to_TO probe_VB a_DT lysate_NN of_IN any_DT other_JJ B._NP bronchiseptica_NN isolate_NN ._SENT Nevertheless_RB ,_, to_TO rule_VB out_RP that_DT RA1_NP antiserum_NN was_VBD unable_JJ to_TO recognize_VB isolate_NN 814_CD antigens_NNS ,_, we_PP performed_VBD another_DT comparative_JJ analysis_NN of_IN antigen_NN expression_NN using_VBG an_DT antibody_NN of_IN well-characterized_JJ specificity_NN :_: antipertactin_NP MAb_NP BPE3_NP ._SENT This_DT antibody_NN was_VBD used_VBN to_TO probe_VB whole-cell_NN lysates_NNS of_IN all_PDT the_DT isolates_NNS by_IN Western_JJ immunoblotting_NN ,_, and_CC then_RB the_DT levels_NNS of_IN pertactin_NN were_VBD quantitated_VBN by_IN densitometry_NN ._SENT While_IN the_DT amounts_NNS of_IN pertactin_NN expressed_VBN by_IN isolates_NNS 222_CD and_CC 629_CD were_VBD very_RB similar_JJ to_TO those_DT expressed_VBN by_IN RB50_NP ,_, isolate_NN 814_CD expressed_VBD less_JJR than_IN one-third_NN of_IN that_DT amount_NN ._SENT In_IN addition_NN ,_, the_DT apparent_JJ molecular_JJ weight_NN of_IN the_DT band_NN detected_VBN in_IN the_DT lysate_NN of_IN isolate_NN 814_CD was_VBD slightly_RB higher_JJR than_IN that_DT of_IN the_DT rest_NN of_IN the_DT isolates_NNS (_( approximately_RB 70,000_CD versus_CC 68,000_CD )_) and_CC matched_VBD the_DT molecular_JJ weight_NN reported_VBN for_IN the_DT B._NP parapertussis_NN pertactin_NN ._SENT Although_IN B._NP bronchiseptica_NP strains_NNS expressing_VBG pertactin_NN isotypes_NNS with_IN the_DT same_JJ molecular_JJ weight_NN as_IN that_DT of_IN the_DT B._NP parapertussis_NN pertactin_NN have_VBP recently_RB been_VBN isolated_VBN ,_, we_PP performed_VBD an_DT additional_JJ test_NN to_TO confirm_VB that_DT isolate_NN 814_CD was_VBD indeed_RB a_DT B._NP bronchiseptica_NN isolate_VBP rather_RB than_IN an_DT unusual_JJ B._NP parapertussis_NN isolate_NN ._SENT As_IN shown_VBN in_IN Table_NP ,_, isolate_NN 814_CD behaved_VBN as_IN a_DT typical_JJ B._NP bronchiseptica_NN strain_NN because_IN ,_, unlike_IN human_JJ isolates_NNS of_IN B._NP parapertussis_NN ,_, it_PP was_VBD oxidase_NN positive_JJ ,_, was_VBD motile_JJ ,_, grew_VBD using_VBG citrate_NN as_IN the_DT only_JJ carbon_NN source_NN ,_, was_VBD able_JJ to_TO reduce_VB the_DT nitrates_NNS to_TO nitrites_NNS ,_, and_CC did_VBD not_RB produce_VB browning_NN on_IN tyrosine_NN agar_NN ._SENT Isolate_VB 814_CD also_RB differed_VBN from_IN ovine_JJ isolates_NNS of_IN B._NP parapertussis_NN in_IN several_JJ of_IN these_DT characteristics_NNS ._SENT The_DT epitope_NN recognized_VBN by_IN MAb_NP BPE3_NP has_VBZ already_RB been_VBN identified_VBN ,_, and_CC we_PP confirmed_VBD that_IN it_PP is_VBZ unaltered_JJ in_IN all_PDT the_DT known_VBN pertactin_NN isotypes_NNS regardless_RB of_IN their_PP$ molecular_JJ weight_NN ._SENT Analysis_NN for_IN the_DT presence_NN of_IN Bordetella-specific_NP DNA_NP sequences_NNS in_IN isolate_NN 814_CD ._SENT |_SYM To_TO provide_VB more_RBR solid_JJ evidence_NN that_WDT isolate_VBP 814_CD was_VBD indeed_RB a_DT B._NP bronchiseptica_NN isolate_NN ,_, we_PP decided_VBD to_TO analyze_VB the_DT isolate_NN for_IN the_DT presence_NN of_IN B._NP bronchiseptica-specific_JJ DNA_NN sequences_NNS ._SENT To_TO do_VB that_IN we_PP constructed_VBD primers_NNS designed_VBN to_TO amplify_VB by_IN PCR_NP a_DT 600-bp_JJ DNA_NN fragment_NN encompassing_VBG the_DT linker-encoding_NN sequences_NNS and_CC some_DT of_IN the_DT transmitter-encoding_JJ sequences_NNS of_IN bvgS_NNS ._SENT A_DT unique_JJ PCR_NP product_NN of_IN the_DT expected_VBN size_NN was_VBD amplified_VBN ,_, cloned_VBN ,_, and_CC sequenced_JJ by_IN using_VBG chromosomal_JJ DNA_NN from_IN isolate_NN 814_CD ._SENT A_DT search_NN with_IN the_DT BLAST_NP program_NN and_CC the_DT deduced_VBN amino_NN acid_NN sequence_NN revealed_VBD that_IN the_DT amplified_VBN region_NN is_VBZ 99_CD %_NN identical_JJ to_TO the_DT B._NP bronchiseptica_NN sequence_NN available_JJ in_IN GenBank_NP ._SENT Compared_VBN to_TO the_DT published_JJ BvgS_NP amino_NN acid_NN sequence_NN ,_, we_PP found_VBD that_IN the_DT sequence_NN of_IN isolate_NN 814_CD contains_VBZ 2_CD amino_NN acid_JJ changes_NNS (_( Met-650-Val_NP and_CC Val-677-Ile_NP )_) over_IN a_DT stretch_NN of_IN 201_CD amino_NN acids_NNS and_CC that_IN both_DT of_IN these_DT substitutions_NNS are_VBP conservative_JJ ._SENT Quantification_NN of_IN the_DT transcriptional_JJ activity_NN of_IN a_DT Bvg-activated_JJ gene_NN in_IN the_DT clinical_JJ isolates_NNS ._SENT |_SYM Since_IN prn_NN is_VBZ transcriptionally_RB activated_VBN by_IN the_DT BvgAS_NP signal_NN transduction_NN system_NN ,_, the_DT reduced_VBN level_NN of_IN expression_NN of_IN pertactin_NN observed_VBN in_IN isolate_NN 814_CD could_MD be_VB due_JJ to_TO a_DT global_JJ decrease_NN in_IN BvgAS_NP activity_NN in_IN this_DT isolate_NN ._SENT If_IN so_RB ,_, this_DT potential_JJ decrease_NN would_MD also_RB affect_VB the_DT expression_NN of_IN other_JJ Bvg-activated_JJ factors_NNS ,_, thus_RB causing_VBG a_DT 